Cargando…
2166. Performance Study on the New ETEST® Piperacillin/Tazobactam (P/T) MIC Strip
BACKGROUND: Piperacillin/Tazobactam combination is a first-line antibiotic and carbapenem sparing option for severe infections due to Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii. ETEST® strips allow to determine antimicrobial Minimum Inhibitory Concentration (MIC). ETEST®...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809554/ http://dx.doi.org/10.1093/ofid/ofz360.1846 |
_version_ | 1783462016984285184 |
---|---|
author | Martelin, Roland Pillon, Edwige Cutivet, Emilie Pompilio, Marion Halimi, Diane Durand, Geraldine |
author_facet | Martelin, Roland Pillon, Edwige Cutivet, Emilie Pompilio, Marion Halimi, Diane Durand, Geraldine |
author_sort | Martelin, Roland |
collection | PubMed |
description | BACKGROUND: Piperacillin/Tazobactam combination is a first-line antibiotic and carbapenem sparing option for severe infections due to Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii. ETEST® strips allow to determine antimicrobial Minimum Inhibitory Concentration (MIC). ETEST® Piperacillin/Tazobactam (Ptc) was developped in 1995 against agar dilution reference method. Since then, resistance to Piperacillin/Tazobactam has been increasing and broth microdilution (BMD) substituted for agar dilution as the reference method. The new ETEST® P/T strip for determining MIC of Enterobacteriaceae, P. aeruginosa and A. baumannii was developed against BMD using a panel of recent strains well genotypically characterized. The aim of this study was to compare the performance of both strips on a panel of challenging strains harboring different-resistant mechanisms. METHODS: A total of 64 strains were tested using ETEST® P/T, ETEST® PTc and BMD: 48 Enterobacteriaceae including 25 resistant strains and 16 P. aeruginosa including 11 resistant strains. The results were analyzed for essential (EA) and category (CA) agreements, minor (mE), major (ME) and very major (VME) error rates using FDA/CLSI 2019 breakpoints (Enterobacteriaceae, P. aeruginosa: ≤ 16/4(S); ≥ 128/4(R) µg/mL). RESULTS: Although the panel of strains was challenging including different resistant mechanisms (acquired penicillinase, high-level cephalosporinase, acquired cephalosporinase, ESBL, carbapenemase), the new ETEST® P/T performance was significantly improved for Enterobacteriaceae with an EA at 92,2% without ME or VME. This improvement was also linked to the easiest reading (significant decrease of microcolonies in the ellipse zone). For P. aeruginosa, the performance was similar between the two strips but the new ETEST® P/T was better correlated with the BMD and showed an EA of 100%. The results are summarized in the table. CONCLUSION: The new ETEST® P/T improved the MIC determination and resistance detection, as well as the reading of MIC end points for the routine use. This study emphasizes the need to check the performance of the antimicrobial susceptibility testing products by testing strains reflecting the current epidemiology. [Image: see text] DISCLOSURES: All authors: No reported disclosures. |
format | Online Article Text |
id | pubmed-6809554 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-68095542019-10-28 2166. Performance Study on the New ETEST® Piperacillin/Tazobactam (P/T) MIC Strip Martelin, Roland Pillon, Edwige Cutivet, Emilie Pompilio, Marion Halimi, Diane Durand, Geraldine Open Forum Infect Dis Abstracts BACKGROUND: Piperacillin/Tazobactam combination is a first-line antibiotic and carbapenem sparing option for severe infections due to Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii. ETEST® strips allow to determine antimicrobial Minimum Inhibitory Concentration (MIC). ETEST® Piperacillin/Tazobactam (Ptc) was developped in 1995 against agar dilution reference method. Since then, resistance to Piperacillin/Tazobactam has been increasing and broth microdilution (BMD) substituted for agar dilution as the reference method. The new ETEST® P/T strip for determining MIC of Enterobacteriaceae, P. aeruginosa and A. baumannii was developed against BMD using a panel of recent strains well genotypically characterized. The aim of this study was to compare the performance of both strips on a panel of challenging strains harboring different-resistant mechanisms. METHODS: A total of 64 strains were tested using ETEST® P/T, ETEST® PTc and BMD: 48 Enterobacteriaceae including 25 resistant strains and 16 P. aeruginosa including 11 resistant strains. The results were analyzed for essential (EA) and category (CA) agreements, minor (mE), major (ME) and very major (VME) error rates using FDA/CLSI 2019 breakpoints (Enterobacteriaceae, P. aeruginosa: ≤ 16/4(S); ≥ 128/4(R) µg/mL). RESULTS: Although the panel of strains was challenging including different resistant mechanisms (acquired penicillinase, high-level cephalosporinase, acquired cephalosporinase, ESBL, carbapenemase), the new ETEST® P/T performance was significantly improved for Enterobacteriaceae with an EA at 92,2% without ME or VME. This improvement was also linked to the easiest reading (significant decrease of microcolonies in the ellipse zone). For P. aeruginosa, the performance was similar between the two strips but the new ETEST® P/T was better correlated with the BMD and showed an EA of 100%. The results are summarized in the table. CONCLUSION: The new ETEST® P/T improved the MIC determination and resistance detection, as well as the reading of MIC end points for the routine use. This study emphasizes the need to check the performance of the antimicrobial susceptibility testing products by testing strains reflecting the current epidemiology. [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6809554/ http://dx.doi.org/10.1093/ofid/ofz360.1846 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts Martelin, Roland Pillon, Edwige Cutivet, Emilie Pompilio, Marion Halimi, Diane Durand, Geraldine 2166. Performance Study on the New ETEST® Piperacillin/Tazobactam (P/T) MIC Strip |
title | 2166. Performance Study on the New ETEST® Piperacillin/Tazobactam (P/T) MIC Strip |
title_full | 2166. Performance Study on the New ETEST® Piperacillin/Tazobactam (P/T) MIC Strip |
title_fullStr | 2166. Performance Study on the New ETEST® Piperacillin/Tazobactam (P/T) MIC Strip |
title_full_unstemmed | 2166. Performance Study on the New ETEST® Piperacillin/Tazobactam (P/T) MIC Strip |
title_short | 2166. Performance Study on the New ETEST® Piperacillin/Tazobactam (P/T) MIC Strip |
title_sort | 2166. performance study on the new etest® piperacillin/tazobactam (p/t) mic strip |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809554/ http://dx.doi.org/10.1093/ofid/ofz360.1846 |
work_keys_str_mv | AT martelinroland 2166performancestudyonthenewetestpiperacillintazobactamptmicstrip AT pillonedwige 2166performancestudyonthenewetestpiperacillintazobactamptmicstrip AT cutivetemilie 2166performancestudyonthenewetestpiperacillintazobactamptmicstrip AT pompiliomarion 2166performancestudyonthenewetestpiperacillintazobactamptmicstrip AT halimidiane 2166performancestudyonthenewetestpiperacillintazobactamptmicstrip AT durandgeraldine 2166performancestudyonthenewetestpiperacillintazobactamptmicstrip |